Evaluation of effective factors on IL-10 signaling in B cells in patients with selective IgA deficiency

Evaluation of effective factors on IL-10 signaling in B cells in patients with selective IgA deficiency.

Journal

European cytokine network
ISSN: 1952-4005
Titre abrégé: Eur Cytokine Netw
Pays: France
ID NLM: 9100879

Informations de publication

Date de publication:
01 03 2022
Historique:
entrez: 14 9 2022
pubmed: 15 9 2022
medline: 17 9 2022
Statut: ppublish

Résumé

Selective IgA deficiency is the most prevalent form of primary immunodeficiencies. The pathogenesis of the disease is still unknown. Several studies have suggested a defect in B cell responses to IL-10; however, the main reason for this defect has not been reported. Elucidating IL-10 signaling defects and their correlation with clinical manifestations could be helpful for better understanding and treatment of the disease. In this study, 15 SIgAD patients and 15 age- and sex-matched healthy controls were included. Surface expression of transforming growth factor β receptor II (TGF-β RII), IL-10R and IgA was assessed by flow cytometry in human purified B cells before and after stimulation by IL-10. Protein expression of STAT3, p-STAT3 and SOCS3 was measured by Western blotting analysis. TGF-β and IgA secretion was evaluated by ELISA. Finally, the measurement of B cell apoptosis was performed by flow cytometry. The TGF-βRII expression level was decreased after stimulation with IL-10 in patients compared with controls. Notably, the TGF-β level were higher after stimulation with mCD40L and IL-10 in the control group as compared to stimulation with mCD40L alone. The IgA+ B cell percentage and IgA secretion levels were significantly increased in controls as compared with SIgAD patients. The relative concentration of the total STAT3 was decreased as compared with controls. The defect in IgA production in SIgAD patients could be due to inadequate B cell responses to IL-10 stimulation that probably originate from defective regulation of IL-10-mediated TGF-b ’symbol’ production TGF-β response by IL-10. Furthermore, it is suggested that the absence of STAT3 protein baseline expression could impair cytokine-mediated signaling such as thatinduced by IL-!0 and IL-21.

Sections du résumé

Background
Selective IgA deficiency is the most prevalent form of primary immunodeficiencies. The pathogenesis of the disease is still unknown. Several studies have suggested a defect in B cell responses to IL-10; however, the main reason for this defect has not been reported. Elucidating IL-10 signaling defects and their correlation with clinical manifestations could be helpful for better understanding and treatment of the disease.
Methods
In this study, 15 SIgAD patients and 15 age- and sex-matched healthy controls were included. Surface expression of transforming growth factor β receptor II (TGF-β RII), IL-10R and IgA was assessed by flow cytometry in human purified B cells before and after stimulation by IL-10. Protein expression of STAT3, p-STAT3 and SOCS3 was measured by Western blotting analysis. TGF-β and IgA secretion was evaluated by ELISA. Finally, the measurement of B cell apoptosis was performed by flow cytometry.
Results
The TGF-βRII expression level was decreased after stimulation with IL-10 in patients compared with controls. Notably, the TGF-β level were higher after stimulation with mCD40L and IL-10 in the control group as compared to stimulation with mCD40L alone. The IgA+ B cell percentage and IgA secretion levels were significantly increased in controls as compared with SIgAD patients. The relative concentration of the total STAT3 was decreased as compared with controls.
Conclusion
The defect in IgA production in SIgAD patients could be due to inadequate B cell responses to IL-10 stimulation that probably originate from defective regulation of IL-10-mediated TGF-b ’symbol’ production TGF-β response by IL-10. Furthermore, it is suggested that the absence of STAT3 protein baseline expression could impair cytokine-mediated signaling such as thatinduced by IL-!0 and IL-21.

Identifiants

pubmed: 36102856
doi: 10.1684/ecn.2021.0464
doi:

Substances chimiques

Immunoglobulin A 0
Transforming Growth Factor beta 0
Interleukin-10 130068-27-8

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-12

Auteurs

Yasser Bagheri (Y)

Stem cell research center, Golestan university of medical sciences, Gorgan, Iran
Immunology department, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Mohsen Saeidi (M)

Stem cell research center, Golestan university of medical sciences, Gorgan, Iran
Immunology department, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Reza Yazdani (R)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
Department of Neurology, Thomas Jefferson University, Philadelphia, Pennsylvania, USA

Fateme Babaha (F)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Reza Falak (R)

Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Gholamreza Azizi (G)

Non-Communicable Diseases Research Center, Alborz University of Medical Sciences, Karaj, Iran

Marjan Taherian (M)

Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Fereshteh Salami (F)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Yaghoob Yazdani (Y)

Stem cell research center, Golestan university of medical sciences, Gorgan, Iran
Immunology department, Faculty of Medicine, Golestan University of Medical Sciences, Gorgan, Iran

Somayeh Sadani (S)

Clinical Research Development Unit (CRDU), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran

Ali Hosseini (A)

Clinical Research Development Unit (CRDU), Sayad Shirazi Hospital, Golestan University of Medical Sciences, Gorgan, Iran

Morteza Motallebnezhad (M)

Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Hassan Abolhassani (H)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran
Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institute at Karolinska University Hospital Huddinge, Stockholm, Sweden

Mehdi Shekarabi (M)

Immunology Research Center, Iran University of Medical Sciences, Tehran, Iran
Department of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Asghar Aghamohammadi (A)

Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children’s Medical Center, Tehran University of Medical Sciences, Tehran, Iran

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH